Amy S. Ruppert

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +14

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema et al. · New England Journal of Medicine · 2018 · 952 citations · Full text

Medicine, Immunology, Oncology +10

Adverse Prognostic Significance of <i>KIT</i> Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study

Peter Paschka, Guido Marcucci, Amy S. Ruppert et al. · Journal of Clinical Oncology · 2006 · 666 citations

Medicine, Hematology, Oncology +17

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski et al. · JAMA Oncology · 2015 · 576 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

<i>BTK</i>^C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn et al. · Journal of Clinical Oncology · 2017 · 471 citations

Medicine, Hematology, Oncology +16